Man (60s) killed in Wexford crash and gardaí arrest man (40s) at scene; man (50s) killed in separate crash in Roscommon - The Irish Independent

ESMO 2025: Disitamab Vedotin plus Toripalimab Versus Chemotherapy in First-Line Locally Advanced or Metastatic Urothelial Carcinoma (la/mUC) with HER2-Expression – UroToday

October 19, 2025

ESMO 2025: Disitamab Vedotin plus Toripalimab Versus Chemotherapy in First-Line Locally Advanced or Metastatic Urothelial Carcinoma (la/mUC) with HER2-Expression UroTodayLoqtorzi Extends Survival in HER2-Positive Advanced Urothelial Cancer CUREtoday.comDisitamab Vedotin/Toripalimab Combo Prolongs Survival in Frontline HER2+ Urothelial Cancer CancerNetworkRC48-C016: DV + Toripalimab Boosts Survival in HER2+ UC Oncodaily